TC-5619

TC-5619 is a nicotinic acetylcholine receptor agonist that was developed by Targacept for the treatment of cognitive disorders, including ADHD and Alzheimer's disease. It was designed to selectively stimulate the α7 subtype of the nicotinic acetylcholine receptor in the brain, which is associated with cognitive function.

History

TC-5619 was first synthesized by Targacept, a biopharmaceutical company based in Winston-Salem, North Carolina. The company was founded in 2000 as a spin-off from R.J. Reynolds Tobacco Company, with the aim of developing drugs that target nicotinic acetylcholine receptors.

Mechanism of Action

TC-5619 is a selective agonist for the α7 subtype of the nicotinic acetylcholine receptor. These receptors are found in the brain and are involved in a variety of cognitive functions, including memory and attention. By selectively stimulating these receptors, TC-5619 is thought to enhance cognitive function and improve symptoms in patients with cognitive disorders.

Clinical Trials

TC-5619 has undergone several clinical trials to evaluate its safety and efficacy in treating cognitive disorders. In a Phase 2 trial for ADHD, the drug showed a statistically significant improvement in symptoms compared to a placebo. However, in a subsequent Phase 2b trial, the drug did not meet its primary endpoint of improving cognitive function in patients with schizophrenia.

Potential Applications

While TC-5619 has not yet been approved for use in any country, it has potential applications in the treatment of a variety of cognitive disorders. These include ADHD, Alzheimer's disease, and schizophrenia. The drug's selective action on α7 nicotinic acetylcholine receptors makes it a promising candidate for these conditions, which are characterized by cognitive impairment.

See Also

• Nicotinic acetylcholine receptor
• Targacept
• Attention deficit hyperactivity disorder
• Alzheimer's disease